Blocking the renin-angiotensin-aldosterone system or lowering the blood pressure: does EUROPA help?

The EUropean trial on Reduction Of cardiac events with Perindopril in stable coronary Artery disease (EUROPA) demonstrated that the angiotensin- converting enzyme inhibitor, perindopril, compared with placebo, in patients with established coronary artery disease, reduced cardiovascular endpoints by 20% over a four-year follow-up period. Although the authors of this study claim that the risk reduction was best explained by blockade of the renin-angiotensin-aldosterone system, reference to recent meta-analyses of blood pressure (BP)-lowering trials provides compelling evidence that the benefits observed in the trial could be explained by the 5/2 mmHg BP difference between active and placebo treatments.